Related Experiment Video
Updated: Apr 25, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Integrase Strand Transfer Inhibitors in HIV Therapy
Thibault Mesplède1, Mark A Wainberg
1McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.
Abstract:
HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S. Food and Drug Administration, health practitioners may soon have access to three integrase strand transfer inhibitors to treat individuals living with HIV. Here, we review the use of raltegravir, elvitegravir, and dolutegravir for use in first- and second-line HIV treatment regimens and the issue of HIV resistance against integrase inhibitors.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Size and Structure of Viral Genomes
Sexually Transmitted Infections
Retroviruses
Viruses with RNA Genomes

